Post-prandial level of GLP-1 is reduced in patients with type 2 diabetes [3], [4], and thus DPP-4 inhibitors and GLP-1 analogues have been widely used for control of plasma glucose (PG) levels in diabetic patients. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.